Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an ...

Thermo Fisher Scientific is shedding its microbiology business to private equity firm Astorg nearly a year after initial ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...

Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading ...

Astellas Pharma has done some spring cleaning of its pipeline, dropping two phase 1 candidates and slamming the brakes on a ...

Both Seaport Therapeutics and Hemab Therapeutics are hoping to bring in around $180 million each from their public listings ...

The 552 million pounds ($747 million) raised by British biotechs in the first quarter of the year has been hailed as a “sign ...

“Our study highlights the growing potential of advanced biomarker science, combined with machine learning, to detect cancers ...

A simple outpatient procedure currently used for type 2 diabetes patients in Europe can help those on Eli Lilly’s obesity ...

Tandem Diabetes Care issued an urgent medical device correction to upgrade the software of its Tandem Mobi insulin pumps that ...

Avalyn Pharma is hoping to rake in around $182 million from an IPO, which the biotech will use to take its inhaled versions ...